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Growing interest in gut and digestive processes and their potential link to brain and
peripheral based inflammation or biobehavioral phenotypes has led to an increasing
number of basic and translational scientific reports focused on the role of gut
microbiota within the context of neuropsychiatric disorders. However, the effect of dietary
modification on specific gut metabolites, in association with immune, metabolic, and
psychopathological functioning in schizophrenia spectrum disorders has not been well
characterized. The short chain fatty acids (SCFA) acetate, butyrate, and propionate,
major metabolites derived from fermentation of dietary fibers by gut microbes, interact
with multiple immune and metabolic pathways. The specific pathways that SCFA are
thought to target, are dysregulated in cardiovascular disease, type II diabetes, and
systemic inflammation. Most notably, these disorders are consistently linked to an
attenuated lifespan in schizophrenia. Although, unhealthy dietary intake patterns and
increased prevalence of immune andmetabolic dysfunction has been observed in people
with schizophrenia; dietary interventions have not been well utilized to target immune
or metabolic illness. Prior schizophrenia patient trials primarily focused on the effects
of gluten free diets. Findings from these studies indicate that a diet avoiding gluten
benefits a limited subset of patients, individuals with celiac disease or non-celiac gluten
sensitivity. Therefore, alternative dietary and nutritional modifications such as high-fiber,
Mediterranean style, diets that enrich the production of SCFA, while being associated
with a minimal likelihood of adverse events, may improve immune and cardiovascular
outcomes linked to premature mortality in schizophrenia. With a growing literature
demonstrating that SCFA can cross the blood brain barrier and target key inflammatory
and metabolic pathways, this article highlights enriching dietary intake for SCFA as a
potential adjunctive therapy for people with schizophrenia.
Keywords: acetate, propionate, butyrate, inflammation, gastrointestinal, psychosis, type II diabetes,
cardiovascular disease
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SCHIZOPHRENIA
Schizophrenia is classically defined as a neurodevelopmental
psychiatric disorder (Lewis and Levitt, 2002). However, the
heterogeneous illness presentation, course, and outcomes
have hindered the development of novel effective treatments.
Schizophrenia is also a neuropsychiatric disorder that results
in significant economic burden (Chong et al., 2016), caregiver
responsibility (Szkultecka-Debek et al., 2016), and global health
disability, since most patients are unable to achieve complete
functional recovery (e.g., consistent paid employment, living
independence, etc.).
Characteristic symptoms of schizophrenia include positive
(delusions, auditory, and visual hallucinations) (Morris et al.,
2012), negative (amotivation, anhedonia, apathy, inappropriate
affect) (Rabinowitz et al., 2012), and dysfunction in multiple
neurocognitive domains including attention (Fioravanti et al.,
2005), learning and memory (Goldman-Rakic, 1994; Gold et al.,
1997; Manoach, 2003), executive functioning (Hutton et al.,
1998), processing speed (Rodriguez-Sanchez et al., 2007), and
IQ (Zammit et al., 2004). More recent studies have consistently
reported deficits in additional neuropsychiatric phenotypes
including social cognition and functioning (Nuechterlein et al.,
2004; Fett et al., 2011), prediction error and reward learning
(Kapur, 2003; Corlett et al., 2007), and sensory gating (Braff and
Geyer, 1990; Hazlett et al., 2015).
The etiology of schizophrenia resembles most chronic
diseases, an interaction of complex environmental and genetic
risk factors. Psychosocial stressors including poor socioeconomic
status (Werner et al., 2007), migration status (Cantor-Graae and
Selten, 2005), lack of social relationships (Jones et al., 1993;
Schenkel et al., 2005), in conjunction with multiple genetic risk
loci (Ripke et al., 2014) and epigenetic modifications (Roth et al.,
2009) leads to alterations in neurotransmitter systems (Tsai et al.,
1995; Howes and Kapur, 2009), neuroimmune activation (Bayer
et al., 1999), brain structure (Suddath et al., 1990; Ho et al., 2003),
and brain functional connectivity (Gur et al., 1985; Andreasen
et al., 1994).
SCHIZOPHRENIA AND ATTENUATED
LIFESPAN
Publications implicating premature mortality as a characteristic
of schizophrenia have been ongoing in the literature for the
past few decades. Some of these past reports have suggested
that attenuated lifespan may be independent of schizophrenia
symptom chronicity. During the 1960’s the primary causes
of mortality in schizophrenia were thought to be due to
the following diseases or illnesses: infection, cardiovascular-
renal, neoplasm, endocrine and metabolic, suicide/accident or
other external causes, and other disease and unspecified causes
(Niswander et al., 1963).
Current estimates suggest that the lifespan for people with
schizophrenia is approximately 28.5 years shorter than the
general population (Olfson et al., 2015). Interestingly, the marked
increase in mortality for people with schizophrenia continues
to largely be a consequence of immune or metabolic illness
exacerbation (Saha et al., 2007) as reported decades ago. Most
recent studies suggest that cardiovascular disease (Hennekens
et al., 2005; Olfson et al., 2015), type II diabetes mellitus
(Olfson et al., 2015), sepsis (Seeman, 2007; Olfson et al., 2015),
gastrointestinal or digestive disease (Dickerson et al., 2016),
autoimmune disorders (Dickerson et al., 2016), influenza and
pneumonia (Olfson et al., 2015) are the major causes of mortality
in schizophrenia. To further complicate matters, these immune
and metabolic disorders have complex convergent and divergent
biological mechanisms (Hotamisligil, 2006). Notably, the gut is
the key functional organ for many of these disorders.
SCHIZOPHRENIA AND GUT BASED
DYSFUNCTION
Comparatively little scientific effort has been focused on
modifying gut-neuropsychiatric pathways in schizophrenia. This
is in part due to our limited knowledge of gastrointestinal (GI)
functioning in relation to schizophrenia disease onset, illness
course, or comorbidities. The extant literature suggests that
multiple immune and metabolic makers are likely to mediate
the relationships between gut functioning and neuropsychiatric
outcomes.
Findings from studies of chronic schizophrenia and bipolar
patients indicate serum elevation of bacterial markers (Severance
et al., 2013) also present on gut microbes, implicating increased
bacterial translocation from the gut. Toxoplasma gondii (bacteria
that infects the GI tract) seropositive status has been linked
to development or progression of multiple neuropsychiatric
diseases, including schizophrenia (Severance et al., 2016b).
Inflammatory GI diseases, especially colitis, are thought to be
highly prevalent (in over 90% of samples) in schizophrenia based
on post mortem biopsy (Hemmings, 1990, 2004). Sex specific GI
dysfunction may also be present in males with schizophrenia due
to Candida albicans exposure (Severance et al., 2016a).
The relationships among schizophrenia illness, diet, and gut
based immune function, is also thought to be present through
the c1q component of the complement pathway (Severance et al.,
2012). Notably, the complement pathway makers and associated
genes are recognized as potential predictors of schizophrenia
genetic risk (Sekar et al., 2016), excessive synaptic pruning (Inta
et al., 2016), and other biological outcomes (Nsaiba et al., 2015).
Taken together, these findings support the role of diet as a
possible environmental factor that contributes to the biochemical
and genetic variation observed in schizophrenia. Moreover,
dietary intake patterns and dietary interventions are increasingly
being explored for their ability to reduce inflammation and
metabolic disease risk, with a minimal likelihood of adverse
effects. Therefore, these and other gut based treatments that
have the potential to target converging immune and metabolic
pathways could be most beneficial for people with schizophrenia.
ARTICLE OBJECTIVES
The remainder of this article will provide an overview of
key observations and treatments associated with metabolic
syndrome and type II diabetes, cardiovascular disease,
Frontiers in Neuroscience | www.frontiersin.org 2 March 2017 | Volume 11 | Article 155
Joseph et al. Mediterranean Diet SCFA Schizophrenia
and inflammation as pertinent to schizophrenia. This
is followed by a brief analysis of dietary intake and the
hypothesized neurobiological mechanisms for unhealthy dietary
intake patterns in schizophrenia. Empirically based dietary
modifications that have been tested in schizophrenia or are
potentially relevant to schizophrenia, short chain fatty acids
(SCFA), immune, and metabolic dysfunction will be reviewed.
Then, the production of SCFA in the colon, their systemic
transport, and findings of the SCFA in the brain and links to
immune and metabolic function most germane to schizophrenia
will be examined. Lastly, alternative dietary modifications,
such as a high-fiber, Mediterranean style diet, that enriches
production of SCFA, will be discussed as a potential adjunctive
treatment for schizophrenia.
SCHIZOPHRENIA, METABOLIC
SYNDROME, AND TYPE II DIABETES
Metabolic syndrome is a combination of three of the following
physiological factors: (1) abdominal obesity, (2) high triglyceride
levels, (3) elevated high density lipoprotein (HDL) levels, (4)
blood pressure, and (5) insulin resistance. It is well recognized
that the incidence of metabolic syndrome, along with the
incidence of type II diabetes that typically follows metabolic
syndrome, is 20% higher in chronic schizophrenia patients
that the general population (Dixon et al., 2000; Mitchell et al.,
2013). Metformin is now being investigated and implemented
as an adjunctive therapy to help mitigate antipsychotic induced
metabolic syndrome (Jarskog et al., 2013).
Although, certain antipsychotic medications (McEvoy et al.,
2005; De Hert et al., 2006), illness chronicity, lifestyle habits such
as diet, smoking, etc., and aging related factors (Subramaniam
et al., 2003) contribute to incidence of metabolic syndrome; a
higher prevalence of metabolic syndrome and type II diabetes
during early stages of (Correll et al., 2014) and antipsychotic
medication naïve (Ryan et al., 2003; Fernandez-Egea et al.,
2009; Pillinger et al., 2017) schizophrenia patients has been
reported. Besides the profound effects metabolic syndrome and
type II diabetes have on premature mortality in schizophrenia,
they have also been associated with poor school performance
in adolescence (de Nijs and Pet, 2016), sensory gating deficits
(Micoulaud-Franchi et al., 2015) and other neurocognitive
outcomes (Lindenmayer et al., 2012; Goughari et al., 2015).
The metabolic syndrome risks associated with schizophrenia
may not be limited to factors that are observed post illness onset.
Maternal type II diabetes is considered a risk factor for fetal
neurodevelopment disorders, including schizophrenia (Cannon
et al., 2002). The hypothesized biological mechanism for this
risk factor is altered docosahexaenoic acid (DHA) transfer to
the fetus (Judge et al., 2016). Therefore, it is not only important
to address metabolic syndrome and diabetes in individuals
who have already been diagnosed with schizophrenia, but to
manage metabolic syndrome and type II diabetes in pregnant
women to reduce the subsequent fetal neurodevelopmental
risk. Notably, the SCFA butyrate has been shown to decrease
metabolic impairments in pregnant mice (Li et al., 2013). Future
studies should also consider the potential fetal neuroprotective
effects of SCFA in models of maternal diabetes and risk for
psychosis.
SCHIZOPHRENIA AND CARDIOVASCULAR
DISEASE
The etiology of cardiovascular disease as relevant to
schizophrenia is multifactorial and complex, with antipsychotic
medications (Peet, 2004), increased incidence of smoking
(McCreadie, 2003; Hennekens et al., 2005), unhealthy dietary
and excess sodium intake (Brown et al., 1999; Teasdale et al.,
2016), sedentary behavior (McCreadie et al., 1998), each having
a substantial role. The primary cardiovascular disease risk
markers that are routinely investigated in schizophrenia include
metabolic syndrome, Framingham 10-year Relative Risk score,
C-reactive protein, and dyslipidemia.
The Framingham 10-year relative risk score is a recognized
tool for predicting future coronary events and has been
validated in various populations (Lakoski et al., 2007). Although,
modifications of the Framingham 10-year relative risk score
calculator have been developed for various research and
treatment programs, the commonly recognized calculator is
comprised of the following factors: sex, age, HDL, and total
cholesterol levels, smoking status, and systolic blood pressure.
Compared to individuals without a psychiatric disorder, the
Framingham 10-year relative risk score is significantly higher in
people with schizophrenia (Goff et al., 2005; Jin et al., 2011).
C reactive protein (CRP), an acute phase protein and
cardiovascular disease risk marker (Ridker, 2001), triggers
other detrimental cardiovascular outcomes such as increased
clotting, generation of oxygen radicals and plaque destabilization
(Prasad, 2006). CRP levels are modulated by the inflammatory
cytokines Interleukin-6 (IL-6) and Tumor Necrosis Factor-α
(TNF-α) that is secreted by macrophages and adipose cells
(Puglisi and Fernandez, 2008). Notably, elevated CRP levels
have been reported in schizophrenia by multiple research groups
(Dickerson et al., 2013; Sicras-Mainar et al., 2013).
Although, cross sectional survey in the general population
indicates a positive relationship between plasma CRP levels and
Framingham 10-year Relative Risk score (Albert et al., 2003), the
exact relationship between Framingham relative risk and CRP
levels in schizophrenia remains unclear. Some research groups
have found a positive association between elevated CRP levels
and Framingham risk score (Sicras-Mainar et al., 2013), whereas
other reports did not observe a significant association (Joseph
et al., 2015). In schizophrenia, both CRP and Framingham risk
have been linked to higher body mass index (BMI) (Miller et al.,
2014; Joseph et al., 2015), psychiatric symptom severity (Barzilay
et al., 2016; Dimitrov et al., 2016), and other dysregulated
metabolic factors including fasting glucose and hemoglobin A1c
levels (Dieset et al., 2012; Joseph et al., 2015). A correlation
between CRP levels and routinely prescribed antipsychotic
medication treatments has also been observed by some groups
(Stefanovic et al., 2015). However, these findings have not been
consistent as other recent findings suggest that antipsychotic
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medications do not target elevated CRP levels in schizophrenia
(Fernandes et al., 2016).
In addition to elevated Framingham relative risk scores
and CRP levels, prominent dyslipidemia has been observed in
schizophrenia (Hennekens et al., 2005; Nasrallah et al., 2006).
In people experiencing early illness stages of schizophrenia,
significant elevations of triglycerides and other non-HDL lipids
has been reported (Correll et al., 2014). In chronic patients, lipid
levels have been linked to psychiatric symptom severity (Solberg
et al., 2015). Pilot studies of pravastatin and simvastatin, lipid
lowering medications, have been conducted in schizophrenia
patients. The preliminary findings from these trials also indicate
these medications also provide a temporary reduction in
inflammation, positive, and negative symptoms (Chaudhry et al.,
2014; Vincenzi et al., 2014). However, larger scale clinical trials
that consider their long-term effects are necessary to replicate and
confirm long-term beneficial outcomes.
Overall, treatment for dyslipidemia, diabetes, and
hypertension has been underutilized in schizophrenia (Nasrallah
et al., 2006). It is important to implement existing treatments and
develop novel interventions directed at reducing cardiovascular
disease risk at early illness stages to improve lifespan and
outcomes in schizophrenia. Therefore, high fiber diets (Ma et al.,
2006) and pharmacological interventions to target cardiovascular
risk factors such as novel anticoagulants, lipid lowering agents,
beta-adrenoreceptor antagonists, and angiotensin converting
enzyme (ACE) inhibitors (Prasad, 2006) are important adjunctive
treatments to consider for people with schizophrenia.
SCHIZOPHRENIA AND INFLAMMATION
Peripheral Inflammation
Multiple immune pathways that accompany systemic
inflammation are dysregulated in schizophrenia. The etiology
of the dysregulated immune activity in schizophrenia has
been linked to multiple causes including maternal infection,
genetics, psychosocial stressors, and other environmental factors
(Muller et al., 2015). The inflammatory cascade serves as a
basic tissue repair mechanism (Schmid-Schonbein, 2006).
Therefore, presence of inflammatory markers indicates that
a tissue injury mechanism is active. However, the source of
systemic inflammation in schizophrenia remains unclear as
high fat diet, obesity, smoking, unhealthy diet, bacterial or
viral infection, and comorbid autoimmune and gastrointestinal
disorders are all likely to have a contributing role in subsets
of symptoms. However, few studies consider all the above
factors when investigating the role of peripheral inflammation
in schizophrenia. Meta-analyses of 40 studies suggests that
interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor growth
factor- β (TGF-β) are cytokines associated with acute symptom
exacerbation whereas TNF-α, interleukin-12 (IL-12), interferon-
γ (IFN-γ), and soluble IL-2 receptor (sIL-2R) levels appear
to remain stable in schizophrenia (Miller et al., 2011). Recent
meta-analyses of case control studies investigating cytokine
genes (Hudson and Miller, 2016), indicates polymorphisms in
IL-1β, IL-6, and soluble IL-6 receptors (sIL6R) are also associated
with risk for schizophrenia.
Neuroinflammation
Elevated peripheral inflammation is closely linked to
neuroinflammation in schizophrenia and other neuropsychiatric
disorders (Hong et al., 2016). Inflammatory cytokines in blood
can cross and interact with astrocytes comprising the blood brain
barrier (Banks et al., 1995; Verkhratsky et al., 2016), circulate into
the brain, and activate microglia (Norden et al., 2016). Chronic
microglia activation causes a subsequent cascade of inflammatory
cytokine activation in the brain that has been linked to aging
brain phenotypes (Norden et al., 2015). Both protein and mRNA
levels of IL-1β, TNF-α, and microglial markers were significantly
increased in postmortem schizophrenia brains in relation to
the brains of comparison subjects (Rao et al., 2013). Microglial
activation is also elevated in people with and ultra-high-risk
for schizophrenia in relation to matched comparison subjects
(Bloomfield et al., 2016), with increased microglial activation
primarily being observed in the hippocampus (Doorduin et al.,
2009). The role of inflammatory cytokines, astrocytes, microglia,
and developmental factors that can lead to neuroinflammation in
psychiatric disorders has been extensively reviewed see (Meyer,
2013; Monji et al., 2013; Na et al., 2014; Verkhratsky et al., 2016).
Treatments for Inflammation
Nonsteroidal anti-inflammatory drug (NSAID) treatment
trials have been conducted to target peripheral and
neuroinflammation. Besides NSAIDs, minocycline (tetracycline
antibiotic), raloxifene (estrogen antagonist), and N-
acetylcysteine (antioxidant precursor) trials are currently
underway to target elevated systemic inflammation in
schizophrenia (Kianimehr et al., 2014). However, their
mechanisms for targeting inflammation vary. The primary
therapeutic efficacy of NSAIDs for systemic inflammation is
via inhibition of cyclooxygenase-2 (COX-2) (Vane and Botting,
1998). Minocycline administration inhibits lipopolysaccharide
(LPS)-induced inflammatory cytokines, major histocompatibility
complex (MHC) II, and Toll-like-receptor (TLR)-2 surface
expression on microglia cells (Garrido-Mesa et al., 2013).
Raloxifene lowers serum levels of IL-6 and TGF-β1 and TNF-α
(Ozmen et al., 2007). N-acetylcysteine modulates the nuclear
factor (NF)-κB associated apoptotic pathway and inflammatory
cytokine (IL-1β, IL-6, TNF-α) levels (Berk et al., 2013).
Inflammation Treatments and
Schizophrenia Phenotypes
Many of the abovementioned treatments are thought to
target schizophrenia relevant phenotypes. Specifically, oral
administration of minocycline reverses altered gut microbes
in hypertension and stress animal models (Wong et al., 2016)
to a composition that is thought to be characteristic of a
healthy gut. Minocycline, is effective at inhibiting microglial
activation at adult stages, whereas it reduces synaptic pruning
and neurogenesis through microglial inhibition during
developmental stages (Inta et al., 2016). This suggests that
minocycline may be a brain developmental stage specific
treatment for neuroinflammation observed schizophrenia.
Raloxifene has demonstrated additional benefits in schizophrenia
including general psychopathology reduction (Kulkarni et al.,
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2016; Usall et al., 2016), improvements in attention and
memory (Weickert et al., 2015), and increased activation in
the right hippocampus and left inferior frontal gyrus (Ji et al.,
2016). N-acetyl cysteine has also demonstrated benefits in
psychopathology symptom reduction (Berk et al., 2013).
Outcomes from prior NSAID trials in schizophrenia patients
suggest low efficacy for celecoxib and inconsistent findings for
aspirin (Sommer et al., 2013). As noted earlier, the estimated
prevalence of inflammatory GI disorders in schizophrenia is high
(Hemmings, 2004), thereby rendering NSAIDs an unsuitable
treatment (Sigthorsson et al., 1998). The number of and
findings from minocycline, raloxifene, and N-acetyl cysteine
trials remains too few and preliminary to determine whether
these treatments will be effective long-term adjunctive treatment
strategies. In addition, these medications do not target the
underlying cause or primary source of peripheral inflammation,
i.e., tissue injury, in schizophrenia, which remains unresolved.
Modified Mediterranean dietary adaptations for enrichment of
SCFA may have great therapeutic value to target inflammation
in schizophrenia. SCFA and specific dietary modifications (Urpi-
Sarda et al., 2012) have demonstrated ability to lower gut and
systemic inflammation.
SCHIZOPHRENIA, OBESITY, AND
UNHEALTHY DIETARY INTAKE
Numerous clinical and epidemiological studies indicate that the
rates of obesity andmorbid obesity for people with schizophrenia
are significantly higher than the general population (Hsiao et al.,
2004; Susce et al., 2005). While elevated BMI is commonly
associated with second generation antipsychotic medication
effects (Grunder et al., 2016); ethnic/racial differences, diet,
physical activity, and other lifestyle factors also contribute to
the prevalence of obesity in schizophrenia (Brown et al., 1999;
Norlelawati et al., 2012).
Current studies of dietary intake in schizophrenia suggest that
most patients have a poor diet largely characterized by increased
fast and processed foods (Strassnig et al., 2003), increased sodium
and cholesterol intake (Nunes et al., 2014), and higher saturated
fat and lower fiber content than non-psychiatric comparison
subjects (Brown et al., 1999; Henderson et al., 2006). Although,
increased sugar and processed diet consumption is thought to
be characteristic of people with schizophrenia originating from
Western and European countries (Peet, 2003; Stokes and Peet,
2004), similar findings have also been observed in patients
from Eastern countries (Sugawara et al., 2014; Ito et al., 2015).
The interaction of sex specific effects for BMI and dietary
consumption in schizophrenia may also be present with female
patients reported to have a higher BMI and unhealthier diet than
males (Amani, 2007; Carliner et al., 2014). Homelessness and
poor socioeconomic status is also likely to have a major influence
on nutritional status and dietary intake patterns in schizophrenia.
However, this has not been taken into consideration for many
studies.
Nutritional changes including ω-3 or vitamin D deficiencies
(Dealberto, 2007) may increase risk for developing psychosis.
A lower intake of ω-6, phytosterols, vitamin A, and vitamin E
(α-tocopherol) has also been reported in relation to BMI and
demographically matched comparison subjects (Nunes et al.,
2014). In addition, consumption of fruit and vegetable portions is
significantly lower that the recommended daily allowance (Heald
et al., 2015). However, other reports indicate that it is primarily
the overall, rather than specific type of, caloric intake that is
increased in schizophrenia (Strassnig et al., 2003). Additional
scientific investigations are needed to clarify the relationships
between lifestyle factors, dietary intake, and nutritional status
in schizophrenia patient populations. Elucidating the specific
role of dietary compounds and nutritional factors in relation to
symptom and behavioral outcomes will require combined efforts
from animal model testing and human clinical trials.
SCHIZOPHRENIA AND NEUROBIOLOGY
OF UNHEALTHY DIETARY INTAKE
The neurobiological and neurocognitive mechanisms that lead
to unhealthy dietary intake by people with schizophrenia are
hypothesized to be related to dysregulated reward circuitry
(Elman et al., 2006): a hyperdopamineric mesolimbic pathway
combined with poor cognitive control (Kapur, 2003). This
pathway has also been implicated in the context of obesity
(Vucetic and Reyes, 2010), food cravings (Blum et al., 2011),
eating disorders (Wagner et al., 2007) and addiction (Volkow
et al., 2012), with altered reward circuitry being a major common
pathway linked to comorbid substance abuse in schizophrenia
(Chambers et al., 2001).
Deficits in reward learning have been observed in multiple
schizophrenia patient studies (Juckel et al., 2006) and have
been consistently linked to co-occurring negative symptoms
(Strauss et al., 2011; Gold et al., 2012). Yet, the ability to alter
responses with the use of prediction error is thought to be intact
for people with schizophrenia (Gold et al., 2012). This could
potentially be utilized as a cognitive strategy to help modify
and improve the quality of dietary intake. However, the specific
relationships between reward circuits and dietary intake patterns
in schizophrenia remain unclear. Novel investigations are needed
to determine the neurocognitive and neurobiological factors that
may be contributing to unhealthy dietary intake and nutritional
status in schizophrenia.
SCHIZOPHRENIA, EMPIRICALLY BASED
DIETS, AND NUTRITIONAL SUPPLEMENTS
Gluten Free Diets
Celiac disease is an autoimmune disorder that results in
inflammatory intestinal damage after the ingestion of food
products containing gluten including wheat, barley, bulgur,
rye, and seitan. Gluten exposure, for individuals with celiac
disease, results in the increase in the expression of HLA antigen
markers on cells in the surface layers of the intestinal mucosa.
T cells react to this and subsequently release IFN-γ, TNF-α,
and other cytokines (Murray, 1999). The incidence of celiac
disease and non-celiac gluten sensitivity (Singh and Kay, 1976;
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Eaton et al., 2006; Cascella et al., 2009; Okusaga et al., 2013)
is higher in schizophrenia that the general population. Celiac
disease and non-celiac gluten sensitivity coincide with elevated
levels of anti-tissue transglutaminase and anti-gliadin antibodies,
respectively (Cascella et al., 2009, 2013). Increased IgG responses
to gluten have also been associated with the activation of
additional immune pathways dysregulated in schizophrenia such
as complement C1q (Severance et al., 2012) in schizophrenia.
Selected case reports and follow up studies indicate that
psychotic symptoms can be triggered by gluten in those with
a gluten intolerance (Lionetti et al., 2015). However, comorbid
non-celiac gluten sensitivity or celiac disease has not been
consistently linked to exacerbation of psychopathology (Cascella
et al., 2009; Jackson et al., 2014). Although, a few studies have
demonstrated that gluten free diets lead to improved symptoms
(Dohan and Grasberger, 1973; De Santis et al., 1997; Jackson
et al., 2012), replication studies have yielded mixed results. In
addition, consumption of a gluten free diet in individuals who
did not have a diagnosis of celiac disease or non-celiac gluten
sensitivity led to lower butyrate levels, reductions in beneficial
gut microbial species, and increased host immune activation
(De Palma et al., 2009). The observed findings may also be
accounted for by decreased intake of fermentable fiber leading to
reduced production of SCFA. Therefore, the implementation of
gluten free diets for schizophrenia patient treatment may be best
limited to those individuals it is most likely benefit; people with
non-celiac gluten sensitivity or celiac disease (Kalaydjian et al.,
2006).
Omega 3 Fatty Acid Supplementation
Omega-3 (ω-3) fatty acids are polyunsaturated fatty acids
involved in cellular metabolism (von Schacky et al., 1985). ω-
3 fatty acids, or their precursor α-linolenic acid, cannot be
synthesized by humans and must be derived from dietary sources
(Harris et al., 2008). The major dietary sources of ω-3 fatty acids
are seafood, poultry, and eggs. α-linolenic acids are largely found
in nuts, soybean, canola, and flax seed oils (Innis, 2008). The ω-
3 fatty acids with prominent immune and metabolic functions
include docosahexaenoic acid (DHA), docosapentaenoic acid
(DPA), and eicosapentaenoic acid (EPA).
ω-3 fatty acids bind to the free fatty acid receptors FFA1
(GPR40) and FFA4 (GPR120). GPR40 receptors are expressed in
pancreatic beta cells and regulate insulin secretion (Itoh et al.,
2003). DHA acts on GPR120 receptors in macrophages and
adipocytes to mediate anti-inflammatory and insulin sensitizing
effects (Oh et al., 2010). Fatty acids also reduce the growth of
the atherosclerotic plaque via reduction in interleukin 1 (IL-
1) and TNF-α and by inhibiting the migration of monocytes
(Zamaria, 2004). Trials of ω-3 fatty acids as a means to improve
cardiovascular health have been effective in reducing sudden
cardiac death (Mozaffarian and Wu, 2011). However, the effects
of ω-3 treatment on other cardiovascular outcomes are not
as clearly delineated. These and other potential relationships
between ω-3 intake and cardiovascular disease risk such as
dyslipidemia should be further examined.
Overall, clinical trials of ω-3 fatty acids in schizophrenia have
demonstrated improvement in psychopathology (Peet, 2006).
Studies comparing EPA and DHA in schizophrenia primarily
indicate symptom improvement with EPA and not DHA (Peet
et al., 2001). This is consistent with the findings for the
roles of EPA and DHA in most mood disorders (Dyall, 2015)
implicating a specific role for EPA in neuropsychiatric function.
Additional reports suggest that ω-3 fatty acids are helpful in
reducing tardive dyskinesia in schizophrenia patients (Emsley
et al., 2002). A recent meta-analyses of randomized trials of ω-
3 supplementation in schizophrenia reported attenuated risk of
conversion to psychosis in prodromal patients (Chen et al., 2015).
In first-episode studies, ω-3 fatty acids decreased non-psychotic
symptoms and improved treatment response rates (Chen et al.,
2015). However, findings from stable chronic schizophrenia
patients are mixed (Chen et al., 2015).
DHA is the primary ω-3 fatty acid in the brain (Dyall, 2015).
Although, this is counterintuitive to the findings of beneficial
effects for EPA rather than DHA or DPA in schizophrenia
and mood disorder clinical trials; significantly lower DHA
concentrations have been observed in the orbitofrontal cortex
of postmortem schizophrenia brains relative to age and gender
matched comparison brains (McNamara et al., 2007). The higher
concentration of DHA observed in the healthy brain may be
linked to its critical roles in enhancing neurogenesis, neurite
outgrowth, and synaptogenesis (Cao et al., 2009). Administration
of EPA + DHA reversed age related reduction in glutamate
receptors GluR2 and NR2B in rodents (Dyall et al., 2007). This
suggest that ω-3 fatty acids may have a key role in synaptic
plasticity and hippocampal glutamatergic transmission that may
be of relevance to the schizophrenia postmortem findings
(McNamara et al., 2007) and other relevant neurobiological
observations (Gao et al., 2000). EPA has also demonstrated
modulatory effects on neurotrophin receptors (Kou et al., 2008).
This may potentially be linked to the observations of reduced
prefrontal cortical expression of neurotrophins in schizophrenia
(Weickert et al., 2005). Follow up studies that account for
potential neurotransmitter and neurotrophic interactions are
needed to clarify the predictors of positive or negative response
EPA, DHA, or DPA in schizophrenia patients across illness course
and lifespan.
Ketogenic Diets
Ketogenic diets are a high-fat, low-carbohydrate, diet routinely
administered to manage treatment refractory epileptic seizures
(Kinsman et al., 1992). Trials of ketogenic diets in non-
psychiatric populations have established their efficacy for short
term weight loss (Foster et al., 2003). Investigation of ketogenic
diets in schizophrenia patient populations have been limited to a
case (Kraft and Westman, 2009) and small pilot study (Pacheco
et al., 1965) with female schizophrenia patients. Consumption
of a ketogenic diet for 2 weeks resulted in improvement in
behavioral symptoms that returned 1 week after discontinuing
the diet (Pacheco et al., 1965).
In a mouse model highly susceptible to seizures (DBA/2J),
ketogenic diet consumption was able to successfully target
sensory gating deficits (Tregellas et al., 2015), a consistently
reported neurocognitive phenotype for schizophrenia spectrum
populations (Earls et al., 2016). In addition, Kraeuter et al. (2015)
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demonstrated that the administration of a ketogenic diet to
NMDA receptor hypofunction mouse model of schizophrenia
(MK-801) normalized model induced behaviors, led to weight
loss, decreased glucose levels, and elevated β-hydroxybutyrate.
β-hydroxybutyrate is a metabolite utilized as an energy source
during ketogenesis, has histone deacetylase inhibitor activities,
and is modulated by SCFA (Selkrig et al., 2014). Notably,
increased serum and urine β-hydroxybutyrate has been observed
in early and chronic schizophrenia patients, implicating a role
for dysregulated energy metabolism (Yang et al., 2013). Yet,
β-hydroxybutyrate is also thought to have potential protective
effects against brain injury and neurodegenerative diseases
via activation of macrophage subsets (Rahman et al., 2014).
Replication of Yang et al.’s findings and additional experiments
will help determine if the elevated β-hydroxybutyrate levels in
schizophrenia are a consequence of impaired energy metabolism
or a compensatory neurodefense mechanism.
However, ketogenic diets can also lead to significant adverse
effects that are salient for individuals with schizophrenia. The
most notable of these include reduced performance on higher
level cognitive tasks based on testing in overweight women
(Wing et al., 1995) and long-term dysregulation of blood
lipid levels that was observed in epilepsy patients (Kwiterovich
et al., 2003). Therefore, the utility of ketogenic diets as an
adjunctive intervention for people with schizophrenia may be
limited. Moreover, since this style of diet drastically reduces
or eliminates carbohydrate consumption, most ketogenic diets
are also likely to be virtually gluten-free (Kraft and Westman,
2009). Larger scale, randomized, trials of ketogenic diets that
account for gluten sensitivity, celiac disease, and assess metabolic,
neurobiological, and behavioral endpoints, will be necessary to
confirm the therapeutic value of ketogenic diets for people with
schizophrenia.
Dietary Approaches to Stop Hypertension
(DASH)
The DASH is a low-sodium, low-fat, diet that was designed with
the aim to improve hypertension (Sacks et al., 2001; Blumenthal
et al., 2010) and reduce the risk for ischemic stroke (Larsson
et al., 2016). Similar to ketogenic diets, DASH diets have been
established as an effective weight loss intervention (Miller et al.,
2002). Small scale investigations of the DASH diet in obese, post-
menopausal, women indicate that the DASH diet may reduce
circulating propionate while increasing acetate and butyrate
(Mathew et al., 2015). Meta-analyses of randomized trials suggest
that DASH diets lead to greater weight loss than other types of
low calorie diets (Soltani et al., 2016).
Studies of the DASH diet in relation to cardiovascular or
psychopathological outcomes in schizophrenia are very limited.
A similar nutritional intervention conducted in a first episode
schizophrenia patient sample was effective at reducing excessive
sodium and caloric intake observed at study baseline (Teasdale
et al., 2016). While the DASH diet and other sodium intake
reduction measures are quite effective at reducing hypertension
and inflammation, compliance has been suboptimal in various
clinical populations (Feyh et al., 2016; Teasdale et al., 2016).
Successful implementation of the DASH or modified DASH
diet to target hypertension or other cardiovascular risk factors
will require cognitive and behavioral modification strategies to
maintain adherence in schizophrenia spectrum populations.
COLONIC GENERATION OF SHORT CHAIN
FATTY ACIDS AND TRANSPORT TO THE
BRAIN
The short chain fatty acids (SCFA) acetate, propionate, and
butyrate are the primary metabolic products derived from the
colonic fermentation of dietary fibers by gut microbes and is
estimated to be produced in a molar ratio of 60:20:20 respectively
(Wong et al., 2006). Table 1 summarizes the major dietary
carbohydrates, primary sources for these carbohydrates, and
identified gut microbiota that ferment these carbohydrates to
produce SCFA.
Short chain fatty acids bind to the free fatty acid receptors
FFAR2 (GPR41) and FFAR3 (GPR43). Propionate binds to
human GPR41 and GPR43 with equal affinity. Acetate has shown
to be selective for GPR43, whereas butyrate preferentially binds
GPR41 (Le Poul et al., 2003). GPR41 expression has been detected
in the autonomic sensory ganglia, pancreas, spleen, lymph nodes,
bone marrow, adipose tissue, and peripheral blood mononuclear
cells including monocytes (Brown et al., 2003; Le Poul et al.,
2003; Nohr et al., 2015). GPR43 expression has primarily been
observed in the colon, ileum, adipose tissue, and immune cells
especially monocytes and neutrophils (Brown et al., 2003; Le
Poul et al., 2003; Nilsson et al., 2003). Expression of these
receptors in human or animal brain models has not yet been well
characterized.
Most of the butyrate that is produced in the colon is taken up
by colonocytes as an energy source (Wong et al., 2006). However,
SCFA are also then transported from the colon via the hepatic
portal vein to the liver. The predominant SCFA that is absorbed
by the liver is propionate for gluconeogenesis (Cummings et al.,
1987). From the liver, SCFA enter the systemic circulation. In
healthy, BMI and lipid level matched, men and women, serum
concentrations of SCFA ranged from 20–190, 1.7–8.4, and 0.0–
7.6 µmol/L for acetate, propionate, and butyrate, respectively
(Wolever and Bolognesi, 1996). Circulating levels of SCFA are
able to cross the blood brain barrier, and the primary SCFA
uptake by the brain is for butyrate, followed by propionate and
acetate (Oldendorf, 1973). In the human brain, butyrate and
propionate concentrations are estimated to be 17.0 and 18.8
pmol/mg, respectively (Bachmann et al., 1979).
SHORT CHAIN FATTY ACIDS AND
INFLAMMATION
Sodium butyrate is anti-inflammatory against LPS induced
inflammation in rat primary microglia, hippocampal cultures,
and neuronal co-cultures of microglial cells, astrocytes and
cerebellar granule neurons (Huuskonen et al., 2004). Butyrate
treatment in hippocampal slice cultures also resulted in the
Frontiers in Neuroscience | www.frontiersin.org 7 March 2017 | Volume 11 | Article 155
Joseph et al. Mediterranean Diet SCFA Schizophrenia
TABLE 1 | Major fermentable dietary carbohydrates and identified gut
microbes associated with colonic acetate, propionate, and butyrate
production.
Major carbohydrate
starting product
Primary dietary
sources for
carbohydrate
starting product
Genus or species of
identified fermenting
microbes
Monosaccharides
Fructose Agave nectar Lactobacillus spp.
Bifidobacterium spp.
Faecalibacterium spp.
Honey
Fruits
Glucosea Squash Faecalibacterium spp.
Apples
Raspberries
Peas
Disaccharides
Lactose Milk Lactobacillus spp.
Bifidobacterium spp.
Streptococcus spp.
Escherichia coli
Yogurt
Buttermilk
Cheese
Sucrose Sugar cane Lactobacillus spp.
Dates
Sugar beets
Sweet peas
Fruits
Oligosaccharides
Fructooligosaccharidesb Onion Bifidobacterium spp.
Chicory
Garlic
Asparagus
Banana
Artichoke
Galactooligosaccharidesb Artichoke Bifidobacterium spp.
Beans
Beetroot
Broccoli
Chickpeas
Fennel
Lentils
Lettuce
Radicchio
Onion
Peas
Raffinose Cottonseed flour Lactobacillus spp.
Bifidobacterium spp.Soy flour
Onions
Chickpeas
Beans
Peas
Lentils
(Continued)
TABLE 1 | Continued
Major carbohydrate
starting product
Primary dietary
sources for
carbohydrate
starting product
Genus or species of
identified fermenting
microbes
Stachyose Cottonseed flour Bifidobacterium spp.
Lactobacillus spp.Soy flour
Onions
Chickpeas
Beans
Peas
Lentils
Polysaccharides
Amylose Potato Bifidobacterium spp.
Eubacterium spp.
Ruminococcus spp.
Prevotella spp.
Corn
Wheat
Tapioca
Rice
Amylopectin Potato Faecalibacterium spp.
Bifidobacterium spp.
Collinsella spp.
Eubacterium spp.
Prevotella spp.
Corn
Wheat
Tapioca
Rice
B glucanb Oat Eubacterium spp.
Atopobium spp.
Enterococcus spp.
Lactobacillus spp.
Prevotella spp.
Clostridium cluster XIVa
Barley
Wheat
Rye
Mushrooms
Seaweed
Gum Arabicb Acacia tree Bifidobacterium spp.
Prepared food additive Lactobacillus spp.
Ruminococcus spp.
Guar Gum Guar bean Bifidobacterium spp.
Ruminococcus spp.Prepared food additive
Inulinb Asparagus Bifidobacterium spp.
Faecalibacterium spp.Leek
Onions
Banana
Wheat
Garlic
Laminarin Seaweed Prevotella spp.
Resistant starchb Cashew Roseburia spp.
Eubacterium spp.
Ruminococcaceae spp.
Green Banana
White Beans
Oat
Potato
Arabinoxylans
Cellulose Seaweed Bifidobacterium spp.
Wheat bran
(Continued)
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TABLE 1 | Continued
Major carbohydrate
starting product
Primary dietary
sources for
carbohydrate
starting product
Genus or species of
identified fermenting
microbes
Pectin Apples Eubacterium spp.
Apricots
Cherries
Oranges
Carrots
Sugar Alcohols
Mannitol Carrots Bifidobacterium spp.
Lactobacillus spp.
Streptococcus spp.
Escherichia spp.
Asparagus
Olives
Sweet potatoes
Pineapple
Mushrooms
Seaweed
Sorbitol Pear Lactobacillus spp.
Streptococcus spp.
Escherichia spp.
Salmonella spp.
Shigella spp.
Prune
Dried rose hip
Peaches
Cherries
Dried fruit mix
Plums
Dates
Xylitol Fruit Bifidobacterium spp.
Streptococcus spp.
Prevotella spp.
Mushrooms
Vegetables
Oats
Corn
Other
Acetate to Butyrate
Conversion
Produced by microbial
fermentation and
contained in food
products made by
bacterial fermentation
Faecalibacterium spp.
Eubacterium spp.
Anaerostipes spp.
Lactate to Butyrate
Conversion
Produced by microbial
fermentation and
contained in food
products made by
bacterial fermentation
Eubacterium spp.
Anaerostipes spp.
Clostridium cluster XIVa
a Is also directly absorbed into the circulation without fermentation by gut microbiota.
b Is recognized to have prebiotic properties (Roberfroid et al., 2010).
downregulation of NF-κB-binding capacity induced by LPS
(Huuskonen et al., 2004).
In addition to targeting brain derived inflammation, SCFA
have the ability to modulate multiple immune and epigenetic
pathways including obesity induced inflammation (Meijer et al.,
2010), IL-6 and TNF-α release from macrophages (Kim et al.,
2014), inhibiting cytokine induced NF-κB activation (Tedelind
et al., 2007), and histone deacetylase inhibition (Wong et al.,
2006). These biological pathways have also been shown to be
dysregulated in schizophrenia (Fan et al., 2007; Sharma et al.,
2008; Song et al., 2009; Miller et al., 2011). Therefore, the
potential of SCFA as an adjunctive treatmentmay have significant
beneficial outcomes. However, the role of SCFA in schizophrenia
risk, onset, and comorbid illness outcomes remains unknown.
Although, the abovementioned studies demonstrate that
SCFA are present in the brain and modify inflammation in a
beneficial manner, administration of valproic acid, a medication
commonly prescribed for symptoms associated with bipolar
disorder and epilepsy, inhibits the transport of SCFA across
the blood brain barrier in rodents (Adkison and Shen, 1996).
In addition, in vitro studies reveal that free fatty acids in
the intestine can have cytotoxic properties (Penn and Schmid-
Schonbein, 2008). Therefore, there is still much to be learned
about the compounds that modulate SCFA and the types and
expression of the receptors that SCFA target. In addition, the role
of SCFA in the brain and their relationship to neurobiological
factors and pathways including neurotransmitter circuits,
neurotrophic factors and other brain metabolites remains largely
unknown.
MEDITERRANEAN STYLE DIETS CAN
TARGET IMMUNE AND METABOLIC
OUTCOMES ASSOCIATED WITH
SCHIZOPHRENIA
Mediterranean based diet treatment trials have led to reductions
in overall cardiovascular disease risk (Estruch et al., 2013)
compared to most Western diets. It is thought that the
Mediterranean diet primarily ameliorates cardiovascular disease
by providing a more optimal ω-6/ω-3 ratio (Simopoulos, 2002).
In addition, adherence to a Mediterranean style diet reduces
levels of CRP and TNF-α (Koloverou et al., 2016; Neale et al.,
2016), immune markers routinely linked to poor cardiovascular
outcomes. In type II diabetes patients, the Mediterranean style
diet significantly reduced hemoglobin A1c levels (Elhayany
et al., 2010), suggesting that a Mediterranean style diet will
likely benefit schizophrenia patients with comorbid type II
diabetes.
In individuals who were defined as healthy based on
screening for autoimmune, cancer, and digestive diseases, a
higher Mediterranean diet score was associated with increased
abundance of health beneficial gut microbiota and coincided
with higher fecal concentrations of propionate and butyrate
(Gutierrez-Diaz et al., 2016). Studies comparing the effects
of Mediterranean style, ketogenic, and low fat diets in obese
individuals indicate that Mediterranean diets are equally effective
as the other diets for weight loss while having the added benefit
of maintaining glycemic and lipid control (Shai et al., 2008). To
our knowledge, studies of Mediterranean diets in schizophrenia
have not yet been conducted. Therefore, incorporating a high-
fiber, ω-3 rich, Mediterranean style diet into patient lifestyle
management and treatment could very likely improve the
metabolic and immune outcomes that have consistently linked to
premature mortality in schizophrenia. Higher fermentable fiber
intake through a modified Mediterranean diet lifestyle should
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increase circulating levels of SCFA and may also directly mitigate
significant constipation, a gastrointestinal side effect associated
with some commonly prescribed antipsychotic medications (De
Hert et al., 2011).
CONCLUSIONS
Dietary modifications and interventions provide an opportunity
to directly target gut, immune, and metabolic markers. This
remains highly underexplored in the context of psychiatric
disorders, especially schizophrenia. Dietary and nutritional
investigations that have been conducted in schizophrenia are few,
with randomized controlled trials of dietary modification being
scarce, thereby leaving a significant gap in the schizophrenia
literature.
Schizophrenia patients are most likely to benefit from
the implementation of individualized dietary interventions
due to co-occurring nutritional deficiencies (Hoffer, 2008;
Kale et al., 2010). Many people with schizophrenia vary
in insight with regards to their illness (Aleman et al.,
2006), dietary intake habits (Heald et al., 2015), social
support (Buchanan, 1995), and everyday functioning
(Sabbag et al., 2012). For dietary interventions in
schizophrenia patient populations to be successful, the
combined support from scientists, dieticians, family
members, and neuropsychiatric clinicians who have been
successful in implementing behavioral modifications will be
necessary.
SCFA can be assayed from blood and fecal samples, and
enriched through high fiber dietary modification. To date, the
role of SCFA in relation to dietary intake, immune, andmetabolic
outcomes has not been investigated in schizophrenia. Therefore,
it is unknown whether high-fiber, Mediterranean type, dietary
modification enriched for SCFA production, could have a direct
effect on improving schizophrenia psychopathology, an additive
effect via concurrent modification of immune and metabolic
markers that may trigger schizophrenia symptoms, or primarily
an indirect effect. Translational animal studies and human
clinical trials will be needed to determine the exact SCFA and
Mediterranean dietary components that can improve short and
long term physiological and behavioral outcomes for people with
schizophrenia.
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